Cadrenal Pivots to CAD-1005, Eyes Phase 3 for Deadly Blood Disorder

Ticker: CVKD · Form: 10-K · Filed: Mar 31, 2026 · CIK: 0001937993

Sentiment: mixed

Topics: Biopharmaceutical, Clinical Trials, Orphan Drug, FDA Fast Track, Drug Development, Thrombotic Disorders, Capital Raise

Related Tickers: CVKD

TL;DR

**CVKD is all-in on CAD-1005 for HIT, but they need cash fast to get to Phase 3, making it a high-risk, high-reward bet.**

AI Summary

Cadrenal Therapeutics, Inc. (CVKD) reported a strategic shift in its primary focus to the development of CAD-1005 for immune-mediated and thrombotic disorders, following the acquisition of a 12-lipoxygenase (12-LOX) platform from Veralox Therapeutics Inc. on December 10, 2025. The company completed an End-of-Phase 2 (EOP2) meeting with the FDA on March 26, 2026, clarifying a potential registrational path for its planned Phase 3 pivotal trial of CAD-1005 in patients with heparin-induced thrombocytopenia (HIT). CAD-1005 holds FDA Orphan Drug Designation for prophylaxis of thrombosis in HIT patients and Fast Track designation for treatment and prevention of HIT, along with an EMA orphan designation for platelet-activating factor 4 disorders. The company's market value of common equity held by non-affiliates was approximately $24,868,103 as of June 30, 2025, with 2,506,817 shares of Common Stock outstanding as of March 27, 2026. Cadrenal also maintains two other clinical-stage assets, tecarfarin and frunexian, but its immediate strategy hinges on securing financing for the CAD-1005 Phase 3 trial. The company has a limited operating history and a history of losses, indicating a significant need for additional capital to fund future operations.

Why It Matters

Cadrenal's strategic pivot to CAD-1005 and its clarified FDA Phase 3 pathway for heparin-induced thrombocytopenia (HIT) is a critical development for investors, signaling a concentrated effort on a single, high-potential asset. Success could offer a novel treatment for HIT, a condition with high morbidity and mortality, potentially impacting patient outcomes significantly. However, the company's reliance on third-party manufacturing and the need for substantial additional financing introduce considerable risk, especially given its limited operating history and history of losses. This move places Cadrenal in direct competition with existing HIT therapies, requiring strong clinical data and market acceptance to carve out a competitive edge.

Risk Assessment

Risk Level: high — Cadrenal Therapeutics faces a high risk level due to its limited operating history, a history of losses, and the explicit statement that its 'cash and the proceeds from our financings will only fund our operations for a limited time,' necessitating additional capital. The company's future success is heavily dependent on the commencement and outcome of its Phase 3 clinical trial for CAD-1005, which is 'subject to obtaining sufficient financing,' as stated in the filing.

Analyst Insight

Investors should closely monitor Cadrenal's ability to secure the necessary financing for its CAD-1005 Phase 3 trial, as this is the immediate critical hurdle. Given the high-risk profile and dependence on a single lead candidate, a speculative position might be considered only after clear progress on funding and trial initiation is demonstrated, or if the risk appetite aligns with early-stage biopharmaceutical ventures.

Financial Highlights

debt To Equity
N/A
revenue
N/A
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
N/A
eps
N/A
gross Margin
N/A
cash Position
N/A
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What is Cadrenal Therapeutics' primary strategic focus after the 10-K filing?

Cadrenal Therapeutics' primary strategic focus is now on the development of CAD-1005 for the treatment of immune-mediated and thrombotic disorders, specifically heparin-induced thrombocytopenia (HIT), following the acquisition of the 12-lipoxygenase (12-LOX) platform in December 2025.

What is the current status of CAD-1005's clinical development for HIT?

CAD-1005 has completed Phase 1 and Phase 2 clinical trials, and Cadrenal Therapeutics held an End-of-Phase 2 (EOP2) meeting with the FDA on March 26, 2026, to clarify the registrational path for its planned Phase 3 pivotal trial in patients with HIT.

Does CAD-1005 have any special regulatory designations?

Yes, CAD-1005 has an Orphan Drug Designation (ODD) from the FDA for the prophylaxis of thrombosis in patients with HIT, an FDA Fast Track designation for the treatment and prevention of HIT, and an orphan designation from the EMA for the treatment of platelet-activating factor 4 disorders.

What are the main financial challenges facing Cadrenal Therapeutics?

Cadrenal Therapeutics has a limited operating history, a history of losses, and explicitly states that its current cash and financing proceeds will only fund operations for a limited time, indicating a significant need to raise additional capital to commence its planned Phase 3 trial for CAD-1005.

What other product candidates does Cadrenal Therapeutics have in its pipeline?

In addition to CAD-1005, Cadrenal Therapeutics' broader pipeline includes tecarfarin, an oral vitamin K antagonist for patients with kidney dysfunction or LVADs, and frunexian, a Phase 2-ready intravenous Factor XIa inhibitor for acute care settings.

What was the market value of Cadrenal Therapeutics' common equity held by non-affiliates?

As of June 30, 2025, the aggregate market value of the voting and non-voting common equity held by non-affiliates of Cadrenal Therapeutics was approximately $24,868,103, based on a closing price of $12.05 per share.

What are the key risks associated with investing in Cadrenal Therapeutics?

Key risks include the company's going concern assumption, limited operating history and history of losses, the need for significant additional capital, dependence on the success of CAD-1005's clinical trials and regulatory approval, and reliance on third-party manufacturers and clinical trial conductors.

When did Cadrenal Therapeutics acquire the 12-LOX platform assets?

Cadrenal Therapeutics acquired the 12-LOX platform assets, including CAD-1005, from Veralox Therapeutics Inc. on December 10, 2025, through an Asset Purchase Agreement.

Will Cadrenal Therapeutics pay dividends in the foreseeable future?

No, Cadrenal Therapeutics explicitly states that it does not intend to pay dividends in the foreseeable future, as indicated in the 'Risks Related to Ownership of Our Common Stock' section of the 10-K filing.

What is heparin-induced thrombocytopenia (HIT) and why is CAD-1005 being developed for it?

Heparin-induced thrombocytopenia (HIT) is a serious, life-threatening prothrombotic complication of heparin administration with high morbidity and mortality. CAD-1005 is being developed as a first-in-class selective 12-LOX inhibitor to address the primary underlying pathophysiology of HIT, unlike existing therapies that only prevent thrombotic complications.

Risk Factors

Industry Context

Cadrenal Therapeutics operates in the biopharmaceutical sector, focusing on the development of novel therapies for life-threatening immune and thrombotic conditions. The market for anticoagulants and treatments for immune-mediated disorders is competitive, with significant ongoing research and development by both large pharmaceutical companies and smaller biotech firms. Key trends include the pursuit of targeted therapies with improved safety profiles and the development of treatments for rare or underserved conditions, such as HIT.

Regulatory Implications

The company's success is heavily dependent on navigating the complex regulatory pathways of the FDA and EMA. Obtaining regulatory approval for CAD-1005, tecarfarin, and frunexian requires rigorous clinical testing and adherence to strict guidelines. The Orphan Drug and Fast Track designations for CAD-1005 offer potential benefits but do not guarantee market approval.

What Investors Should Do

  1. Monitor financing activities closely.
  2. Track FDA feedback on the Phase 3 trial protocol.
  3. Evaluate the competitive landscape for HIT treatments.
  4. Assess the progress of tecarfarin and frunexian.

Key Dates

Glossary

12-lipoxygenase (12-LOX)
An enzyme involved in inflammatory and thrombotic pathways. Inhibiting this enzyme is the mechanism of action for CAD-1005. (Central to the company's primary strategic focus with CAD-1005.)
Heparin-Induced Thrombocytopenia (HIT)
A serious immune-mediated condition that causes a sudden drop in platelet count and an increased risk of blood clots after exposure to heparin. (The primary indication for the lead product candidate, CAD-1005.)
End-of-Phase 2 (EOP2) meeting
A meeting between a drug developer and the FDA to discuss the results of Phase 2 trials and the plan for Phase 3 trials, seeking alignment on the path to approval. (Crucial for defining the registrational strategy for CAD-1005.)
Orphan Drug Designation (ODD)
A status granted by regulatory agencies (like the FDA and EMA) to drugs intended to treat rare diseases, offering incentives such as market exclusivity and tax credits. (CAD-1005 has ODD for HIT, potentially providing market advantages.)
Fast Track designation
A process by the FDA to expedite the development and review of drugs for serious conditions that fill an unmet medical need. (CAD-1005 has Fast Track designation for HIT, indicating potential for accelerated development and review.)
Tecarfarin
An oral vitamin K antagonist (VKA) designed as a warfarin replacement for patients with complex needs, particularly those with kidney dysfunction or LVADs. (One of the company's other clinical-stage assets.)
Frunexian
A first-in-class, Phase 2-ready intravenous Factor XIa inhibitor for acute care settings. (Another clinical-stage asset in the company's broader pipeline.)
Factor XIa inhibitor
A type of anticoagulant drug that targets Factor XIa, a protein in the blood clotting cascade, to prevent thrombosis. (The mechanism of action for Frunexian.)

Year-Over-Year Comparison

Information regarding year-over-year comparisons, including revenue growth, margin changes, and new risks, is not available in the provided text. The filing focuses on the company's current strategic direction, recent acquisitions, and clinical development plans, particularly for CAD-1005 following the Veralox asset purchase in December 2025.

Filing Stats: 4,432 words · 18 min read · ~15 pages · Grade level 14.1 · Accepted 2026-03-31 09:02:23

Key Financial Figures

Filing Documents

Business

Business 3 Item 1A.

Risk Factors

Risk Factors 25 Item 1B. Unresolved Staff Comments 63 Item 1C. Cybersecurity 63 Item 2.

Properties

Properties 63 Item 3.

Legal Proceedings

Legal Proceedings 63 Item 4. Mine Safety Disclosures 63 PART II 64 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 64 Item 6. [Reserved] 65 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 65 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 67 Item 8.

Financial Statements and

Financial Statements and Supplementary Data F-1 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 68 Item 9A.

Controls and Procedures

Controls and Procedures 68 Item 9B. Other Information 69 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 69 PART III 70 Item 10. Directors, Executive Officers and Corporate Governance 70 Item 11.

Executive Compensation

Executive Compensation 77 Item 12.

Security Ownership of Certain

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 84 Item 13. Certain Relationships and Related Transactions, and Director Independence 86 Item 14. Principal Accountant Fees and Services 87 PART IV 88 Item 15. Exhibits and Financial 88 Item 16. Form 10-K Summary 88 i PART I

Forward-Looking Statements

Forward-Looking Statements This Annual Report on Form 10-K (this "Annual Report") contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part I, Item 1. "Business," Part I, Item 1A. "Risk Factors," and Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations," but are also contained elsewhere in this Annual Report in some cases you can identify forward-looking statements by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based on our current beliefs, expectations, and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed, projected or implied in or by the forward-looking statements. You should refer to Part I, Item 1A. "Risk Factors" section of this Annual Report for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We do not undertake any obligation to update

Business

Item 1. Business. The Company We are a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. As a result of our acquisition of a 12-lipoxygenase ("12-LOX") platform of assets in December 2025 (as described in more detail below), we transitioned our primary strategic focus to the development of CAD-1005 for the treatment of immune-mediated and thrombotic disorders. Our lead product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia ("HIT"), a deadly immune-mediated thrombotic disorder. CAD-1005 has been evaluated in a blinded, placebo-controlled study Phase 2 clinical trial of 24 patients as well as Phase 1 clinical trials in more than 100 patients. On March 26, 2026, we completed our End-of-Phase 2 ("EOP2") meeting with the FDA and clarified a potential registrational path for our planned Phase 3 pivotal trial of CAD-1005 in patients with HIT. Our Phase 3 trial protocol will still be subject to additional information which may be set forth in the final meeting minutes from the FDA and any further comments we may receive from the FDA upon their review of the protocol. CAD-1005 has an orphan drug designation ("ODD") from the FDA for the prophylaxis of thrombosis in patients with HIT, as well as an FDA Fast Track designation for the treatment and prevention of HIT, and an orphan designation from the EMA for the treatment of platelet-activating factor 4 disorders. Our broader pipeline includes two additional clinical-stage assets—tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist ("VKA") (a warfarin replacement for patients with complex needs) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Specifically, our focus for tecarfarin is for chronic use in patients with kidney dysfunction or left ventricular assist devices ("LVADs"). Tecarfarin

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing